compounded sublingual semaglutide drops 15ml – BloomMD Oral semaglutide drops - No

The STEP 1 trial of once-weekly injectable semaglutide reported substantial average weight loss in adults with obesity, as published in the New England Journal of Medicine

A RECENT study has identified a potential link between the use of semaglutide, a glucagon-like peptide 1 receptor agonist (GLP-1 RA), and an increased risk of developing nonarteritic anterior ischemic optic neuropathy (NAION) in patients with type 2 diabetes (T2D) or those who are overweight or obese

Lean proteins, easily digestible carbohydrates, and cooked vegetables are better tolerated

Not all B12 forms are equal

For millions of people who have been curious about GLP-1s but hesitant about injections, this moment feels like science just removed a very sharp needle from the equation